L’avènement des nouvelles molécules en oncologie, notamment les thérapies ciblées, a entraîné une amélioration de la survie des patients par rapport à la chimiothérapie standard. Les toxicités rénales de ces agents anticancéreux sont de plus en plus reconnues et sont variables selon la cible thérapeutique visée. Cet article passe en revue la toxicité rénale associée aux thérapies ciblées anticancéreuses dirigées contre Epidermal growth factor receptor, Human epidermal growth factor-2, B-rapidly accelerated fibrosarcoma, Mitogen-activated protein kinase, Anaplastic lymphoma kinase, Programmed cell death-1/programmed cell death ligand-1, Cytotoxic T lymphocyte antigen-4 et Vascular endothelial growth factor/receptor. Le diagnostic et la prise en charge précoces de ces événements indésirables rénaux sont essentiels pour le clinicien en charge de ces patients.

The advent of new molecules oncology including targeted therapies, has resulted in improved patient survival over standard chemotherapy. The renal toxicities of these anticancer agents are more and more recognized and vary according to the targeted therapeutic target. This article reviews the renal toxicity associated with targeted anticancer therapies directed against Epidermal growth factor receptor, Human epidermal growth factor-2, B-rapidly accelerated fibrosarcoma, Mitogen-activated protein kinase, Anaplastic lymphoma kinase, Programmed cell death-1/programmed cell death ligand-1, Cytotoxic T lymphocyte antigen-4 and Vascular endothelial growth factor/receptor. The early diagnosis and management of these renal adverse events is essential for the clinician who cares for such patients.